Cite
HARVARD Citation
Charles-Schoeman, C. et al. (2016). Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the rheumatic diseases. 75 (7), pp. 1293-1301. [Online].